Inetetamab

DRUG14 trials

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Peking Union Medical College, Zhiyong Yu, Sun Yat-sen University, Chinese Academy of Medical Sciences

Conditions

Breast CancerBreast Neoplasm FemaleBreast NeoplasmsHER2-positive Advanced Breast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast CancerMetastatic Breast CancerNon-small Cell Lung Cancer

Phase 1

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Sun Yat-sen UniversityNon-small Cell Lung Cancer

Start: 2021-07-28End: 2025-02-01Target: 48Updated: 2021-08-23

Phase 2

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBreast Cancer

Start: 2020-09-09End: 2024-09-09Target: 71Updated: 2020-12-23

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Zhiyong YuMetastatic Breast Cancer

Start: 2021-08-01End: 2024-07-31Target: 100Updated: 2021-07-15

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer HospitalBreast Neoplasms

Start: 2022-05-20End: 2026-01-01Target: 120Updated: 2023-09-25

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

The First Affiliated Hospital with Nanjing Medical UniversityBreast Cancer

Start: 2022-02-13End: 2025-12-31Target: 30Updated: 2023-09-14

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Not yet recruitingNCT07366840

Fudan UniversityHER2-positive Breast Cancer, Metastatic Breast Cancer

Start: 2026-01-16End: 2029-01-16Target: 268Updated: 2026-01-26

Phase 3

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Not yet recruitingNCT04736589

Peking Union Medical CollegeBreast Cancer

Start: 2021-02-02End: 2027-02-02Target: 270Updated: 2021-02-03

Phase 4

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Chinese Academy of Medical SciencesBreast Cancer

Start: 2022-03-12End: 2025-12-31Target: 70Updated: 2022-03-23

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

RecruitingNCT06641544

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityMetastatic Breast Cancer

Start: 2024-10-17End: 2027-12-31Target: 200Updated: 2024-10-15

Unknown Phase

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Zhiyong YuHER2-positive Advanced Breast Cancer

Start: 2021-07-31End: 2021-12-31Target: 100Updated: 2021-07-15

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

The First Affiliated Hospital with Nanjing Medical UniversityBreast Neoplasms

Start: 2020-01-01End: 2024-03-31Target: 100Updated: 2023-03-27

A Real-world Study of Inetetamab for First-line Treatment of MBC

Not yet recruitingNCT05980208

Hunan Cancer HospitalBreast Cancer, Real-world Study

Start: 2023-09-01End: 2026-12-31Target: 150Updated: 2023-08-08

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

RecruitingNCT06234137

Wang OuchenBreast Neoplasm Female

Start: 2021-11-27End: 2031-08-01Target: 154Updated: 2024-01-31

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

CompletedNCT06305702

Liaoning Cancer Hospital & InstituteHER2-positive Metastatic Breast Cancer

Start: 2022-07-01End: 2024-01-31Updated: 2024-03-12

Related Papers

Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.

Journal of Clinical Oncology2024-06-01

Abstract PO1-04-04: Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial

Cancer Research2024-05-021 citations

Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer

MedComm2024-04-294 citations

Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.

2023-10-306 citations

Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial.

2023-10-0710 citations

Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.

Journal of Clinical Oncology2023-06-012 citations